Speaking at the launch, Samarth Jain, Chief Executive Officer, Positive Bioscience said, “Each year 1 million cases of Cancer are reported and nearly 700,000 Cancer patients die every year as nearly 80% patients are diagnosed in last stage (i.e. Stage-4).” RNA sequencing test offers 99% accuracy and it tests 25,000 genes.
On the key role of RNA sequencing technology, Jain further added, “Currently, 1 in 12,000 Indian goes for RNA sequencing, while in the US 1 in every 10 Americans prefer this test for diagnosing Cancer. However, in next 2-3 years India can also see 1 in every 10 people prescribed for RNA sequencing, if the awareness regarding this technology is spread quicker and wider.
According to Jain, in case of lung Cancer merely 6-9 genes are tested to diagnose, but RNA sequencing tests 25,000 genes, which takes to accurate diagnosis. In India nearly 75,000 new lung Cancer cases are reported each year.
“While diagnosing lung cancer with conventional diagnosis of Cancer, majority of the patients are prescribed for ALK tests and out of which 30% fails. This means, nearly 22,500 lung Cancer patients are expected to diagnosed wrong this year”, noted Jain.
On cost efficiency, Jain informed, “DNA sequencing of 1 gene costs around Rs. 6,000, so testing 9 genes takes the cost to Rs. 54,000 and still chances of misdiagnosis are still loom. On the other hand, the RNA sequencing costs Rs. 49,000.”
PositiveSelect is a comprehensive genomic solution for solid tumors (Lung Cancer, Breast Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, etc.) as well as Hematological Cancers (Leukemia, Lymphoma, Myeloma, etc.), designed to provide oncologists with clinically actionable report, which can identify the molecular alterations in a patient’s tumor and match those alterations with relevant targeted therapies and clinical trials.